The study focuses on people living with HIV-1 infection who are already taking long‑term antiretroviral medication. Even with treatment, the virus can hide in cells, cause ongoing low‑grade chronic inflammation, and lead to a gradual weakening of the immune system known as immune senescence. The trial will compare an oral tablet containing the drug dasatinib (50 mg) with an inactive substance called placebo to see if the active drug can safely reduce the hidden virus, lower inflammation, and improve immune function.
The purpose of the study is to determine whether adding dasatinib can change the number and activity of important immune cells, specifically the white‑blood‑cell types called CD4, CD8 and CD56+. Participants will take either dasatinib or placebo for about a year, with regular clinic visits where blood samples are taken at several intervals (early after starting, then roughly every few months) to measure these cells, inflammation signals, and any side effects. Terms such as “viral reservoir” refer to the hidden virus that remains in cells despite treatment, and “inflammation markers” are blood signals that show how much inflammation is present.
Throughout the trial, doctors will closely watch for any adverse events, meaning any unwanted medical problems, and will perform routine laboratory tests to ensure safety. The study will track how the immune cells and inflammation markers change over time, providing information on whether dasatinib can offer additional benefit to people already on antiretroviral therapy.
Spain 
